Abstract
Pancreatic cancer is one of the most resistant cancers to conventional treatment modalities and is generally in the locally advanced or metastatic stage at the time of initial diagnosis. Approximately only 20% of patients are diagnosed as potentially resectable but 5-year survival rate is no more than 20-25% even in these resectable ones. Realizing the poor prognosis with a single-modality approach, several studies that used the combination of chemotherapy and radiotherapy with surgery are performed in order to improve local control and survival. This review evaluates the existing data and future aspects about the combined modality treatment in locally advanced pancreatic cancer regarding both the efficiency and toxicity of these combinations and novel agents.
Keywords: pancreaticoduodenectomy, chemotherapy, intraoperative radiotherapy (IORT), adenocarcinoma, neoadjuvant therapy, streptozocin, computed tomographic (CT), gemcitabine
Current Cancer Therapy Reviews
Title: Recent Advances in Combined Modality Treatment for Locally Advanced Pancreatic Cancer
Volume: 1 Issue: 3
Author(s): Gorkem Aksu, Binnaz Sarper, Cuneyt Ulutin and Hakan Bakkal
Affiliation:
Keywords: pancreaticoduodenectomy, chemotherapy, intraoperative radiotherapy (IORT), adenocarcinoma, neoadjuvant therapy, streptozocin, computed tomographic (CT), gemcitabine
Abstract: Pancreatic cancer is one of the most resistant cancers to conventional treatment modalities and is generally in the locally advanced or metastatic stage at the time of initial diagnosis. Approximately only 20% of patients are diagnosed as potentially resectable but 5-year survival rate is no more than 20-25% even in these resectable ones. Realizing the poor prognosis with a single-modality approach, several studies that used the combination of chemotherapy and radiotherapy with surgery are performed in order to improve local control and survival. This review evaluates the existing data and future aspects about the combined modality treatment in locally advanced pancreatic cancer regarding both the efficiency and toxicity of these combinations and novel agents.
Export Options
About this article
Cite this article as:
Aksu Gorkem, Sarper Binnaz, Ulutin Cuneyt and Bakkal Hakan, Recent Advances in Combined Modality Treatment for Locally Advanced Pancreatic Cancer, Current Cancer Therapy Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339405774574199
DOI https://dx.doi.org/10.2174/157339405774574199 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From TGF-β to Cancer Therapy
Current Drug Targets Gene Therapy to Improve Pancreatic Islet Transplantation for Type 1 Diabetes Mellitus
Current Diabetes Reviews The Disposal of Reactive Carbonyl Species through Carnosine Conjugation: What We Know Now
Current Medicinal Chemistry An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Associating Paracrine Communication to Regenerative Medicine: Search Strategies & Major Trends in Scientific and Patent Production
Recent Patents on Regenerative Medicine Estrogens and Thyroid Hormones: Non-Genomic Effects are Coupled to Transcription
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting Type 1 Diabetes Before and at the Clinical Onset of Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Electrochemical Immunosensors for Disease Detection and Diagnosis
Current Medicinal Chemistry Preservation Solutions for Solid Organ Transplantation
Mini-Reviews in Medicinal Chemistry The Global Component-Target Network in Panax Ginseng C
Letters in Drug Design & Discovery Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs
Current Drug Metabolism Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes
Current Vascular Pharmacology Cytokine Network: New Targeted Therapy for Pancreatic Cancer
Current Pharmaceutical Design Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T)
Current Genomics The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics Human Serum Albumin Conjugated Biomolecules for Cancer Molecular Imaging
Current Pharmaceutical Design Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit
Infectious Disorders - Drug Targets Enzyme Stereospecificity as a Powerful Tool in Searching for New Enzymes
Current Drug Metabolism